EGFR and neoplasm: The association of EGFR with an immune-desert tumour phenotype with poor response to checkpoint inhibitor therapies has been observed in several clinical trials.60,61 Mutations of PRKAR1A have been recently demonstrated to drive a drastic remodelling of the tumour microenvironment.